Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)
Open Access
- 1 October 2021
- Vol. 39 (43) , 6422-6436
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp and Dohme United Kingdom
This publication has 26 references indexed in Scilit:
- Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)MMWR. Morbidity and Mortality Weekly Report, 2015
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in AdultsNew England Journal of Medicine, 2015
- Recommendations for Pneumococcal Immunization Outside Routine Childhood Immunization Programs in Western EuropeAdvances in Therapy, 2014
- Pneumococcal infection in adults: burden of diseaseClinical Microbiology and Infection, 2014
- Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of ageVaccine, 2014
- Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and olderVaccine, 2013
- The Impact of 7-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease: A Literature ReviewAdvances in Therapy, 2013
- Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate VaccinesClinical Microbiology Reviews, 2012
- Comparative analysis of two ratesStatistics in Medicine, 1985
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIALBiometrika, 1934